92873-89-7

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(2-chlorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique chemical structure allows it to serve as a building block in the creation of new medicinal compounds.
Used in Agrochemical Synthesis:
In the agrochemical industry, 1-(2-chlorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one is also utilized as an intermediate in the development of different agrochemical products, contributing to its wide range of applications.
Used in Organic Chemistry:
1-(2-chlorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one holds potential in the field of organic chemistry, where it can be employed in various chemical reactions and processes to produce a diverse array of organic compounds.
Used in Material Science:
1-(2-chlorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one's unique structure also makes it a candidate for applications in material science, where it may be used to develop new materials with specific properties.
Safety Precautions:
It is important to handle and store 1-(2-chlorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one with caution due to its potential health and environmental hazards. Proper safety measures should be taken to minimize risks associated with its use.

Upstream product

• 2142-68-9 1-(2-chlorophenyl)ethanone 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 640741-04-4 C₁₉H₁₄ClN₃O 
• 1032917-42-2 1-(2-chlorophenyl)-3-(1H-indol-3-yl)-3-(4-methoxyphenyl)propan-1-one 
• 22252-15-9 trans-4-methoxychalcone 
• 1336985-12-6 (E)-ethyl 2-(6-(2-chlorophenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-pyran-2-ylidene)acetate 
• 1336985-14-8 (E)-ethyl 2-(6-(2-chlorophenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-pyran-2-ylidene)acetate 
• 1611461-11-0 9-(4-methoxyphenyl)-2,3:6,7-dibenzobicyclo[3.3.1]nona-2,6-diene-4,8-dione 

Relevant academic research and scientific papers

From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity

A ligand-based approach involving systematic modifications of a trisubstituted pyrazoline scaffold derived from the COX2 inhibitor, celecoxib, was used to develop novel PDE5 inhibitors. Novel pyrazolines were identified with potent PDE5 inhibitory activit

Synthesis and cytotoxicity evaluation of new 3-substituted 4-(4-methyloxy phenyl)-1H-pyrrole derivatives

A new series of 3-substituted 4-(4-methyloxy phenyl)-1H-pyrrole derivatives were synthesized and biologically evaluated for potential anticancer activity. Fifteen targeted compounds showed high selectivity toward normal cells and cancer cells: that is, al

Antimycobacterial and anti-inflammatory activities of substituted chalcones focusing on an anti-tuberculosis dual treatment approach

Tuberculosis (TB) remains a serious public health problem aggravated by the emergence of M. tuberculosis (Mtb) strains resistant to multiple drugs (MDR). Delay in TB treatment, common in the MDR-TB cases, can lead to deleterious life-threatening inflammation in susceptible hyper-reactive individuals, encouraging the discovery of new anti-Mtb drugs and the use of adjunctive therapy based on anti-inflammatory interventions. In this study, a series of forty synthetic chalcones was evaluated in vitro for their anti-inflammatory and antimycobacterial properties and in silico for pharmacokinetic parameters. Seven compounds strongly inhibited NO and PGE2 production by LPS-stimulated macrophages through the specific inhibition of iNOS and COX-2 expression, respectively, with compounds 4 and 5 standing out in this respect. Four of the seven most active compounds were able to inhibit production of TNF-α and IL-1β. Chalcones that were not toxic to cultured macrophages were tested for antimycobacterial activity. Eight compounds were able to inhibit growth of the M. bovis BCG and Mtb H37Rv strains in bacterial cultures and in infected macrophages. Four of them, including compounds 4 and 5, were active against a hypervirulent clinical Mtb isolate as well. In silico analysis of ADMET properties showed that the evaluated chalcones displayed satisfactory pharmacokinetic parameters. In conclusion, the obtained data demonstrate that at least two of the studied chalcones, compounds 4 and 5, are promising antimycobacterial and anti-inflammatory agents, especially focusing on an anti-tuberculosis dual treatment approach.

COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF

Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.

Synthesis of chalcone derivatives as potential anti-diabetic agents

Chalcones bearing electron donating or electron withdrawing substitutions were prepared and their glucose uptake activity was evaluated. Chalcone derivatives were synthesized in one step protocol with high purity and yield. Chalcones with chloro, bromo, iodo and hydroxy substitutions at position 2 on A-ring exhibited the highest activity with glucose medium concentration (210 to 236 mg/dl) compared to pioglitazone and rosiglitazone (230 and 263 mg/dl, respectively). Also chalcones with iodo substitution at position 3 on A-ring were comparably active (≤ 238 mg/dl). The structure-activity relationship of the tested chalcones was studied and the findings were supported statistically.

Development of a formal catalytic asymmetric [4 + 2] addition of ethyl-2,3-butadienoate with acyclic enones

Allene esters are unique not only as excellent electrophiles but also because of their ability for subsequent reactivity after the initial nucleophilic attack. A mechanistically inspired cyclization using ethyl-2,3-butadienoate and acyclic enones to provi